NYSE:JNJ
148.32
0.21
(0.14%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia
Analysis and Opinions about JNJ-N
Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 21, 2020
(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
Show full opinionHide full opinion
(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
BUY
BUY
January 14, 2020
Has long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
Show full opinionHide full opinionHas long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
TOP PICK
TOP PICK
January 10, 2020
His model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
Show full opinionHide full opinionHis model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
TOP PICK
TOP PICK
January 8, 2020
In an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
Show full opinionHide full opinionIn an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
BUY
BUY
December 19, 2019
Given the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
Show full opinionHide full opinionGiven the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
BUY
BUY
December 18, 2019
SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.
TOP PICK
TOP PICK
December 16, 2019
Breaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
Show full opinionHide full opinionBreaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 11, 2019
If you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
Show full opinionHide full opinionIf you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 5, 2019
The drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
Show full opinionHide full opinionThe drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
DON'T BUY
DON'T BUY
November 21, 2019
JNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Show full opinionHide full opinionJNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
TOP PICK
TOP PICK
November 19, 2019
It's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
Show full opinionHide full opinionIt's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
COMMENT
COMMENT
November 7, 2019
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
Show full opinionHide full opinionHigh opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
BUY WEAKNESS
BUY WEAKNESS
November 5, 2019
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.
DON'T BUY
DON'T BUY
October 17, 2019
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
Show full opinionHide full opinionWouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
TOP PICK
TOP PICK
October 15, 2019
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
Show full opinionHide full opinion$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
